A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.

Scientists have demonstrated a creative new way to kill cancer cells effectively, with few side effects. Gluing two ...

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer BenefitPRAME-TCR iNKT Overcomes Challenges from ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

About Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatry (Treg) cell therapies that aims to harness, direct and optimize their immune suppressive properties ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

At CPHI Milan 2024, Abzena highlighted its enhanced cell line development platform ... Abzena also showcased its high-potency ...

Research by Mayo Clinic suggests that senolytic drugs could improve bone health in older women by targeting senescent cells, ...

“With that comes improvement in efficacy and potency.” Radiant’s technology ... from the receptor it is targeting on activated T cells and natural killer cells. Activating this receptor ...

For example, fans may occasionally find a piece of gear that increases "Potency" or "Warding" when equipped, and they may be uncertain about the specific benefits of raising those stats.